JGA acts as a legal advisor for Celon Pharma S.A. in their public stock offering

The JGA team provided legal advisory services to Celon Pharma S.A., headquartered in Kiełpino, in the preparation of the prospectus for a planned public offering. Celon Pharma S.A. is an integrated biopharmaceutical company engaged in research, development, manufacturing, and sale of pharmaceutical products. In recent years, the company has introduced various products to the market, including a generic asthma drug called Salmex, as well as medications used in the treatment of breast cancer, Alzheimer’s disease, schizophrenia, and HIV support.

In relation to the prospectus, Celon Pharma S.A. sought approval and listing on the regulated market (WSE) for up to 30 million shares, with 15 million shares included in the public offering. The prospectus of Celon Pharma S.A. was approved by the Financial Supervision Commission on 29 August 2016, and the debut of Celon Pharma S.A. on the Warsaw Stock Exchange took place on 17 October 2016. The value of the public offering amounted to PLN 245 million, making it the largest initial public offering in 2016.

JGA’s advisory scope specifically included legal advice in the preparation of the prospectus.

The above project was carried out by the JGA team, supervised by Grzegorz Morawiec, Magdalena Jackowicz-Korczyńska, Karolina Wolnicka, and Natalia Skutnik-Golecka.